Claims for Patent: 8,735,359
✉ Email this page to a colleague
Summary for Patent: 8,735,359
Title: | Combinations of modalities for the treatment of diabetes |
Abstract: | A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith. |
Inventor(s): | Orban; Tihamer (Brookline, MA) |
Assignee: | Orban Biotech LLC (Brookline, MA) |
Application Number: | 13/534,571 |
Patent Claims: | 1. A method of treating diabetes mellitus in a subject comprising administering to the subject: a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) fusion protein in
a pharmaceutically acceptable carrier, and preproinsulin in a pharmaceutically acceptable carrier.
2. The method of claim 1, wherein said CTLA4 fusion protein is abatacept. 3. The method of claim 1, wherein said preproinsulin comprises amino acids 33-47 of SEQ ID NO:1. 4. The method of claim 1, wherein said pharmaceutically acceptable carrier is an oil-based carrier. 5. The method of claim 4, wherein said oil-based carrier is IFA or Montanide ISA. |
Details for Patent 8,735,359
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | 12/23/2005 | ⤷ Try a Trial | 2039-03-29 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 07/29/2011 | ⤷ Try a Trial | 2039-03-29 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 06/07/2016 | ⤷ Try a Trial | 2039-03-29 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 03/30/2017 | ⤷ Try a Trial | 2039-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.